Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YYD302 in Knee Osteoarthritis
NCT02965495Phase 2Completed
- Sponsor
- Yooyoung Pharmaceutical
- Start
- Nov 2016
- Primary completion
- Sep 2017
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of YYD302 in osteoarthritis (OA) (3 arms), sponsored by Yooyoung Pharmaceutical. Primary endpoint: Rate of change of the Weight-bearing pain (100mm-VAS) at 12 weeks. Started Nov 2016; status: completed.
02
Drugs
YYD302
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02965495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02965495.